Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma

Ribeiro, Maria João Marques; Alonso, Teresa; Gajate, Pablo; Barquin, Arantzazu; Perna, Cristian; Grande, Enrique.
Autops. Case Rep ; 8(1): e2018005, Jan.-Mar. 2018. ilus
Artículo en Inglés | LILACS | ID: biblio-905466

Documentos relacionados

  1. Chemotherapy in NETs: When and how.
  2. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.
  3. [Case of Unresectable Gastric Mixed Neuroendocrine Neoplasm(MiNEN)Treated with Chemotherapy].
  4. Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.
  5. Management of well-differentiated neuroendocrine tumors.
  6. Chemotherapy in NEN: still has a role?
  7. Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes.
  8. Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET).
  9. Tris-Functionalized Polyoxotungstovanadate-Mediated Antitumor Efficacy Involves Multiple Cell Death Pathways.
  10. Somatostatin analogs in pregnant patients with neuroendocrine tumor.